An Edge-based Architecture for Phasor Measurements in Smart Grids

This paper investigates the application of Kubernetes and Edge computing technologies to operate IT services in the context of power systems and smart grids. Traditional services for grid monitoring such as Phasor Measurement Units (PMUs) and Phasor Data Concentrators (PDCs) require a centralized architecture and a rigid networking infrastructure in order to properly function, which today is only achieved at the High Voltage (HV) transmission level. Furthermore, manual intervention is often the only option for PMUs/PDCs maintenance. In this work, the traditional PMU/PDC services were deployed as docker-containers in a decentralized Kubernetes cluster, which can represent any kind of geographically dispersed TCP/IP network. By leveraging remote orchestration, several key benefits are achieved: (1) no manual reconfiguration of the PMU-PDC communications upon network reconfiguration, (2) automatic PMU traffic redirection in case of PDC service redeployment in a different location, and (3) reduced data-loss upon PDC failure and enhanced overall system resiliency due to minimized ICT services down-time

Intorno al viaggio musicale di Andrea Zanzotto

Starting from Viaggio musicale, a small book curated by Paolo Cattelan in dialogue with Andrea Zanzotto on the theme of music and poetry, the article follows the path of formation of the poet to music: the nursery rhymes of childhood, Toti Dal Monte and the Opera arias sung by the villagers, the theatre of puppets and music by Margot Galante Garrone, Federico Fellini and Nino Rota, the musicians who met his poetry and set it to music

Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study

Background Metastatic breast cancer (MBC) is an incurable disease and its treatment focuses on prolonging patients' (pts) overall survival (OS) and improving their quality of life. Eribulin is a microtubule inhibitor that increases OS in pre-treated MBC pts. The most common adverse events (AEs) are asthenia, neutropenia and peripheral neuropathy (PN). Methods PAINTER is a single arm, phase IV study, aimed at evaluating the tolerability of eribulin in MBC pts. Secondary objectives were the description of treatment efficacy and safety, the assessment of the incidence and severity of PN and its association with genetic polymorphisms. Genomic DNA was isolated from blood samples and 15 Single Nucleotide Polymorphisms (SNPs) were genotyped by Taqman specific assays. The association between PN and SNPs were evaluated by Fisher exact test. Results Starting from May 2014 until June 2018 180 pts were enrolled in this study by 20 Italian centers. 170 of these pts could be evaluated for efficacy and toxicity and 159 for polymorphisms analysis. The median age of pts was 60 years old and the biological subtypes were luminal type (64.7%), Her2 positive (18.3%) and triple negative (17%). Pts were pretreated with a median of 5 lines for MBC. The median follow up of this study was 15.4 months with a median number of 4.5 cycles administered (minimum-maximum 1-23). The median overall survival was 12 months. 48.8% of pts experienced a dose reduction, mainly for neutropenia (23.9%) and liver toxicity (12%). 65 pts (38.2%) reported at least one severe toxicity. Neutropenia and neurotoxicity were the most frequent severe AEs (15.3% and 14.7%, respectively); other reported toxicities were osteo-muscular, abdominal or tumor site pain (19.4%), liver toxicity (6.6%), pulmonary toxicity (6.5%) and dermatological toxicity (3.6%). Among the 15 evaluated SNPs, an association with PN was found for rs2233335 and rs7214723. Conclusions Eribulin is a well-tolerated treatment option in MBC. Schedule and dosage modifications were common, but toxicity rarely led to treatment discontinuation. SNPs rs2233335 (G/T and T/T) in the NDRG1 gene and rs7214723 (CC and CT) in the CAMKK1 gene were associated with PN. These findings, if validated, could allow a tailored treatment with eribulin in cancer patients. Trial registration: ClinicalTrials.gov ID: NCT02864030